InMed Pharmaceuticals (FRA:MWG) ROCE % : -116.78% (As of Dec. 2024)

View and export this data going back to 2004. Start your Free Trial

What is InMed Pharmaceuticals ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. InMed Pharmaceuticals's annualized ROCE % for the quarter that ended in Dec. 2024 was -116.78%.

InMed Pharmaceuticals ROCE % Historical Data

The historical data trend for InMed Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

InMed Pharmaceuticals ROCE % Chart

InMed Pharmaceuticals Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

-89.55

-139.41

-171.27

-76.84

-74.35

InMed Pharmaceuticals Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
ROCE %	Get a 7-Day Free Trial															-50.60	-56.65	-74.51	-73.12	-116.78

InMed Pharmaceuticals ROCE % Calculation

InMed Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	-7.556	/	( ( (13.02 - 1.847)	+	(10.984 - 1.832) )	/ 2 )
	=	-7.556	/	( (11.173	+	9.152)	/ 2 )
	=	-7.556	/	10.1625
	=	-74.35 %

InMed Pharmaceuticals's ROCE % of for the quarter that ended in Dec. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Dec. 2024 )		(Q: Sep. 2024 )		(Q: Dec. 2024 )
	=	-8.492	/	( ( (9.429 - 1.294)	+	(8.119 - 1.71) )	/ 2 )
	=	-8.492	/	( ( 8.135	+	6.409 )	/ 2 )
	=	-8.492	/	7.272
	=	-116.78 %

(1) Note: The EBIT data used here is four times the quarterly (Dec. 2024) EBIT data.

InMed Pharmaceuticals (FRA:MWG) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

InMed Pharmaceuticals ROCE % Related Terms

Thank you for viewing the detailed overview of InMed Pharmaceuticals's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

InMed Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » InMed Pharmaceuticals Inc (FRA:MWG) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

INM:USA MWG:Germany

Address

885 West Georgia Street, Suite 1445, Vancouver, BC, CAN, V6C 3E8

Website

https://www.inmedpharma.com

InMed Pharmaceuticals Inc is a Canada based clinical-stage biopharmaceutical company. The company is engaged in the research and development of novel, cannabinoid-based, and manufacturing of Pharmaceutical grade cannabinoids. Its product portfolio includes INM-755, which is used for the treatment of epidermolysis bullosa; INM-088 for the treatment of glaucoma; INM-901 for Alzheimer's disease, INM-089's pharmacological and IntegraSyn which is a manufacturing system for Pharmaceutical-Grade Cannabinoids.